New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)

April 26, 2019 Off By BusinessWire

— Efficacy Demonstrated Across Measures Not Addressed by Current
Therapies —

— New Data at the 2019 American Association of Clinical
Endocrinologists (AACE) Scientific and Clinical Congress Demonstrates
Significant Proptosis Reduction and Improvement in Overall Response Rate
—

DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc (Nasdaq: HZNP) today announced that new data from the
Phase 3 confirmatory clinical trial (OPTIC) evaluating the
investigational medicine teprotumumab for the treatment of active
thyroid eye disease (TED) were presented as part of a late-breaking oral
presentation at the 2019 American Association of Clinical
Endocrinologists (AACE) Scientific and Clinical Congress in Los Angeles.
In addition to primary endpoint data previously announced
on Feb. 28, 2019, the presentation includes new data from two secondary
endpoints that show a dramatic reduction in proptosis (eye bulging) and
a substantial improvement in overall response rate in patients treated
with teprotumumab compared with placebo. These data demonstrate the
potential for teprotumumab as a treatment for Active TED, which
currently has no U.S. Food and Drug Administration (FDA) approved
treatments. Teprotumumab is an investigational medicine and its safety
and efficacy have not been established.

“People living with Active TED who received teprotumumab in the study
achieved key outcomes that are not addressed by current therapeutic
approaches,” said Raymond Douglas, M.D., Ph.D., the study’s co-principal
investigator and director of the orbital and thyroid eye disease
program, Cedars-Sinai Medical Center, who presented the data at AACE.
“Currently, patients with Active TED suffer through life-altering
symptoms and – once the active phase of disease ends – are often left
with permanent damage. The results of this confirmatory study, together
with the Phase 2 results, suggest that teprotumumab may help reduce
proptosis and alleviate the inflammatory symptoms of Active TED,
potentially avoiding the need for multiple complex surgeries.”

The primary endpoint of the Phase 3 confirmatory trial, titled OPTIC
(Treatment of Graves’ Orbitopathy
(Thyroid Eye Disease) to Reduce Proptosis
with Teprotumumab Infusions
in a Randomized, Placebo-Controlled, Clinical
Study), was the percentage of patients with a ≥ 2 mm reduction of
proptosis from baseline in the study eye without deterioration of
proptosis in the non-study eye at study week 24. Horizon previously
reported that, in the intent-to-treat population, 34/41 (82.9%) patients
receiving teprotumumab and 4/42 (9.5%) patients receiving placebo were
proptosis responders at Week 24 (p˂0.001).

The following new data on two secondary endpoints was presented at AACE:

- Average change in proptosis throughout 24 weeks of treatment:
  - - Throughout the 24 week treatment period, patients treated with
      teprotumumab had an average proptosis reduction of 2.82 mm
      compared with 0.54 mm for those who received placebo (p<0.001).
  - - There was a significant difference in proptosis reduction from
      baseline between teprotumumab and placebo at all study time
      points: Week 6 (-2.00 mm vs. -0.38), Week 12 (-2.70 vs. -0.64),
      Week 18 (-3.26 vs. -0.59) and Week 24 (-3.32 vs. -0.53).

- Overall responder rate at Week 24, which includes proptosis reduction
  of ≥2 mm plus Clinical Activity Score (CAS) improvement of ≥2 points,
  was significantly better for patients treated with teprotumumab. CAS
  is a scale used to assess the disease activity of TED, and measures
  the degree of inflammation, including pain, swelling and redness.
  - - Patients treated with teprotumumab had an overall responder rate
      of 78% compared with 7.1% in the placebo group at week 24
      (p<0.001).
  - - Overall response rate to teprotumumab was significantly better
      than placebo from baseline at all study time points: Week 6 (43.9%
      vs. 4.8%), Week 12 (63.4% vs. 11.9%), Week 18 (73.2% vs 11.9%) and
      Week 24 (78.0% vs. 7.1%).

- As previously reported, all secondary OPTIC trial endpoints were met
  (p≤0.001), which – in addition to the above – include the effect of
  teprotumumab vs. placebo on:
  - - Percent of participants with a CAS value of 0 or 1 at Week 24 in
      the study eye.
  - - Percent of patients with a change from baseline of at least one
      grade in diplopia (double vision).
  - - Mean change in Graves’ Ophthalmopathy (GO) Quality of Life
      questionnaire from baseline to Week 24.

“After initially sharing primary endpoint results from the OPTIC trial,
this is the first of several additional presentations that will explore
and analyze secondary endpoints – all of which met statistical
significance,” said Shao-Lee Lin, M.D., Ph.D., executive vice president,
head of research and development and chief scientific officer, Horizon
Pharma plc. “As Horizon continues its evolution into a research focused
company, we strive to address some of the most challenging and
overlooked rare diseases. We’ve met with and learned from the thyroid
eye disease community – those living with the disease and the physicians
who treat them – and these interactions have given us urgency to bring
forward an effective option where none currently exist.”

As previously reported, the safety profile of teprotumumab in OPTIC was
similar to that seen in the Phase 2 study with no new safety
observations. The drop-out rate was low (<5%) and balanced across
placebo and treatment arms. There were no deaths during the study and a
total of three serious adverse events: in the placebo arm, one patient
had a visual field defect and received orbital decompression surgery and
discontinued study; in the teprotumumab arm, one patient had
pneumothorax (considered not related to study drug) and another had an
infusion reaction that led to discontinuation of study drug. The vast
majority of treatment-emergent adverse events were mild to moderate in
intensity and no other adverse events resulted in discontinuation.

TED is a progressive and debilitating autoimmune disease with a limited
window of active disease during which it may respond to medical
intervention.^1,2 While TED often occurs in people living with
hyperthyroidism or Graves’ disease, it is a distinct disease that is
caused by autoantibodies activating an IGF-1R-mediated signaling complex
on cells within the orbit.^3,4 This leads to a cascade of
negative effects, which may cause long-term, irreversible damage. Active
TED lasts for up to three years and is characterized by inflammation and
tissue expansion behind the eye.^5,1 As TED progresses, it
causes serious damage – including proptosis (eye bulging), strabismus
(misalignment of the eyes), and diplopia (double vision) – and in some
cases can lead to blindness.^2,6 Currently, patients must
suffer through Active TED until the disease becomes inactive – often
left with permanent and sight-impairing consequences – before they may
need complex and costly surgical procedures that may never fully restore
vision or appearance.^5,1,7 People living with TED often
experience long-term functional, psychological and economic burdens,
including inability to work and perform activities of daily living.^7,8
There are currently no U.S. Food and Drug Administration (FDA) approved
treatments for Active TED.

Data Briefing on Horizon Website

On Monday, April 29, Horizon will post an audio presentation featuring
Dr. Douglas, who will review his OPTIC data presented at AACE. The
webcast may be accessed at http://ir.horizon-pharma.com.

About Teprotumumab

Teprotumumab is a fully human monoclonal antibody (mAb) and a targeted
inhibitor of the insulin-like growth factor 1 receptor (IGF-1R). The
robust clinical development program for teprotumumab in the treatment of
TED includes positive results from the Phase
3 OPTIC confirmatory clinical trial as well as positive Phase 2
results which were published in The
New England Journal of Medicine. Horizon expects to submit a
Biologics License Application to the U.S. Food and Drug
Administration (FDA) in mid-2019. Teprotumumab has received Breakthrough
Therapy, Orphan Drug and Fast Track designations from the FDA. The OPTIC
trial was conducted at leading centers in the U.S., Germany and Italy,
with co-principal investigators Raymond Douglas, M.D., Ph.D.,
Cedars-Sinai Medical Center; and George Kahaly, M.D., Johannes Gutenberg
University Medical Center. Horizon is also conducting the OPTIC‐X
extension trial to gather further insight into the long-term
efficacy and safety of teprotumumab. Teprotumumab is an investigational
medicine and its safety and efficacy have not been established.

About Horizon Pharma plc

Horizon Pharma plc is focused on researching, developing and
commercializing innovative medicines that address unmet treatment needs
for rare and rheumatic diseases. By fostering a growing pipeline of
medicines in development and exploring all potential uses for currently
marketed medicines, we strive to make a powerful difference for
patients, their caregivers and physicians. For us, it’s personal: by
living up to our own potential, we are helping others live up to theirs.
For more information, please visit www.horizonpharma.com,
follow us @HZNPplc on
Twitter, like us on Facebook or
explore career opportunities on LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements, including
statements regarding expectations regarding the submission of a BLA for
teprotumumab, potential regulatory approval of teprotumumab and the
potential for teprotumumab as a treatment for TED. Forward-looking
statements speak only as of the date of this press release and Horizon
does not undertake any obligation to update or revise these statements,
except as may be required by law. These forward-looking statements are
based on management’s expectations and assumptions as of the date of
this press release and actual results may differ materially from those
in these forward-looking statements as a result of various factors.
These factors include, but are not limited to, risks regarding whether
Horizon Pharma experiences delays in submitting a BLA for teprotumumab,
whether the FDA will accept the planned BLA for filing or approve the
BLA, risks associated with clinical development of medicine candidates
and whether Horizon Pharma will be able to successfully commercialize
teprotumumab, if approved. For a further description of these and other
risks facing Horizon Pharma, please see the risk factors described in
Horizon Pharma’s filings with the United States Securities and Exchange
Commission, including those factors discussed under the caption “Risk
Factors” in those filings. Forward-looking statements speak only as of
the date of this press release and Horizon Pharma undertakes no
obligation to update or revise these statements, except as may be
required by law.

References

1. Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment,
  and Management. Journal of Ophthalmology. 2015. https://www.hindawi.com/journals/joph/2015/249125/cta/.
  Accessed Feb 22, 2019.

1. The 2016 European Thyroid Association/European Group on Graves’
  Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. European
  Thyroid Journal. 2 March 2016. https://www.ncbi.nlm.nih.gov/pubmed/27099835.
  Accessed Feb 22, 2019.

1. Graves’ Ophthalmopathy. The New England Journal of Medicine. 25
  February 2010. https://www.nejm.org/doi/full/10.1056/NEJMra0905750.
  Accessed Feb 22, 2019.

1. Igs from patients with Graves’ disease induce the expression of T cell
  chemoattractants in their fibroblasts. The Journal of Immunology. 15
  January 2002. https://www.ncbi.nlm.nih.gov/pubmed/11777993.
  Accessed Feb 22, 2019.

1. Update on thyroid eye disease and management. Clinical
  Ophthalmology. 19 October 2009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770865/.
  Accessed Feb 22, 2019.

1. Clinical features of dysthyroid optic neuropathy: a European Group on
  Graves’ Orbitopathy (EUGOGO) survey. British Journal of
  Ophthalmology. 11 October 2006. https://www.ncbi.nlm.nih.gov/pubmed/17035276.
  Accessed Feb 22, 2019.

1. Quality of Life and Occupational Disability in Endocrine Orbitopathy. DA
  International. 24 April 2009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689575/.
  Accessed Feb 22, 2019.

1. Public health relevance of Graves’ orbitopathy. The Journal of
  Clinical Endocrinology & Metabolism. 26 November 2012. https://www.ncbi.nlm.nih.gov/pubmed/23185037.
  Accessed Feb 22, 2019.

C-HZN-00132